Holen Sie sich die Stockscreener-App
26.72
1.62%
-0.44
Handel nachbörslich:
26.72
Schlusskurs vom Vortag:
$27.16
Offen:
$27.25
24-Stunden-Volumen:
389.12K
Relative Volume:
0.41
Marktkapitalisierung:
$1.59B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-14.14
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-9.18%
1M Leistung:
+3.77%
6M Leistung:
+33.70%
1J Leistung:
+24.28%
1-Tages-Spanne:
$26.68
$28.05
1-Wochen-Bereich:
$26.43
$29.42
52-Wochen-Spanne:
$13.30
$30.22
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
26.72 | 1.61B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Is Enliven Therapeutics Inc. stock attractive for income investorsProduct Launch & Daily Stock Trend Watchlist - mfd.ru
Breakout Zone: Whats the RSI of ARRPRC stockTrade Entry Summary & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
History Review: Can Enliven Therapeutics Inc disrupt its industryWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Will Enliven Therapeutics Inc. benefit from rising consumer demandWeekly Trade Report & Fast Gain Swing Trade Alerts - mfd.ru
Candriam S.C.A. Raises Stock Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $145,200.00 in Stock - MarketBeat
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares By Investing.com - Investing.com UK
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares - Investing.com
Aug Technicals: What drives Enliven Therapeutics Incs stock priceJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Bear Alert: Will AdvanSix Inc stock hit new highs in YEARQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year HighWhat's Next? - MarketBeat
Quarterly Trades: Is Enliven Therapeutics Inc a speculative investment2025 Support & Resistance & Free Verified High Yield Trade Plans - baoquankhu1.vn
Aug Highlights: How sensitive is Enliven Therapeutics Inc to inflation2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k - AOL.com
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast - Defense World
Update Report: Can Enliven Therapeutics Inc disrupt its industryPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress - Sahm
Enliven Therapeutics Executive Sells 20,000 Shares - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Pioneer with 61% Potential Upside - DirectorsTalk Interviews
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aug Sectors: What is DATSs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Market Outlook: Is Enliven Therapeutics Inc attractive for institutional investorsStop Loss & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com - Investing.com South Africa
Day Trade: What hedge funds are buying TSLA2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Lyssikatos, Enliven Therapeutics CSO, sells $535k in ELVN stock By Investing.com - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares - MarketBeat
Enliven Therapeutics director Heyman sells $32,901 in stock - Investing.com
Why (ELVN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Comparing CytoDyn (OTCMKTS:CYDY) and Enliven Therapeutics (NASDAQ:ELVN) - Defense World
Stocks To Watch: Enliven Therapeutics Sees RS Rating Jump To 85 - Investor's Business Daily
Assessing Enliven Therapeutics (ELVN) Valuation After Positive Phase 1b ENABLE Trial Update - Sahm
Will Enliven Therapeutics Inc. stock see insider buyingChart Signals & Short-Term Swing Trade Alerts - bollywoodhelpline.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.4%Should You Buy? - MarketBeat
Have Enliven Therapeutics Insiders Been Selling Stock? - Sahm
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Is Enliven Therapeutics Inc. attractive for institutional investorsQuarterly Market Summary & High Return Trade Opportunity Guides - bollywoodhelpline.com
Moving Averages: Does Enliven Therapeutics Inc stock have upside surprise potential2025 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 48,300 Shares of Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $1.35m in ELVN - Investing.com Canada
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares of Stock - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 91,198 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 41,302 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $241,164.05 in Stock - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares By Investing.com - Investing.com UK
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):